Ocular Therapeutix vs Spero Therapeutics
OCUL and SPRO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How OCUL and SPRO compare
Ocular Therapeutix is the larger company, worth 25 times as much as Spero Therapeutics ($1.5B against $59.4M).
Spero Therapeutics grew revenue faster over the last twelve months (−3.3% versus −9.7% for Ocular Therapeutix).
Spero Therapeutics keeps more of each dollar of sales as profit, with a net margin of 15.7% compared with −649% at Ocular Therapeutix.
Spero Therapeutics scores higher on the StockData Score (11 against 3 for Ocular Therapeutix), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | OCUL | SPRO |
|---|---|---|
| Size and price | ||
| Market cap | $1.5B | $59.4M |
| Share price | $6.66 | $1.02 |
| Change, 1 year | −38.5% | −59.2% |
| Change, 5 years | −0.45% | −93.8% |
| Beta (5Y) | 1.26 | 1.13 |
| Employees | 325 | 25 |
| StockData Score | ||
| Total score | 3 | 11 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 3 (better) |
| Health score | 3 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 25.5× |
| P/S | 29.0× | 1.3× (better) |
| P/B | 3.3× | 1.3× (better) |
| EV/EBITDA | – | 1.4× |
| FCF yield | −18.3% | – |
| Fair value | $4.81 | $1.72 |
| Margin of safety | −38.5% | 40.7% (better) |
| Growth | ||
| Revenue growth (TTM) | −9.7% | −3.3% (better) |
| Revenue growth, 5Y average | 24.4% | 48.2% (better) |
| Profitability | ||
| Gross margin | 87.3% | – |
| Operating margin | −681% | 12.8% (better) |
| Net margin | −649% | 15.7% (better) |
| FCF margin | −530% | – |
| Return on equity | −93.5% | 19.2% (better) |
| Financial health | ||
| Debt / equity | 0.17 (better) | 0.00 |
| Interest coverage | −30.6× | – |
| Current ratio | 9.12 (better) | 6.12 |
| Altman Z-score | 1.28 (better) | −6.00 |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 94.4% | 36.9% |
| Held by insiders | 2.9% | 24.6% |
| Insider net buying, 12 months | −$2.5M | −$499K (better) |
| Short interest, % of float | 13.6% | 1.8% |
Go deeper
- OCUL stock overview
- OCUL income statement
- OCUL valuation and score
- SPRO stock overview
- SPRO income statement
- SPRO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.